Contact lens having a TRPM8 agent releasedly attached to a polymeric lens body
Contact lenses with TRPM8 agonist and antagonist combinations address the issue of initial discomfort by delivering cooling while minimizing stinging/burning, enhancing comfort and satisfaction.
Patent Information
- Application Number
- KR1020267016107
- Authority / Receiving Office
- KR · KR
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2023-10-27
- Filing Date
- 2024-10-25
- Publication Date
- 2026-11-06
- Estimated Expiration
- 2044-10-25
AI Technical Summary
Contact lenses containing TRPM8 agonists provide a pleasant cooling sensation but often cause stinging or burning upon initial insertion, reducing wearer comfort.
Incorporating a TRPM8 agonist and antagonist into contact lenses, where the agonist is released during wear to provide cooling and the antagonist is delivered initially to mitigate stinging/burning sensations.
The combination of TRPM8 agonist and antagonist in contact lenses enhances comfort by reducing initial discomfort and providing sustained cooling sensation without stinging/burning, improving wearer satisfaction.
Smart Images

Figure 112026061708756-PCT00011_ABST
Abstract
Description
Technology Field
[0001] The field of the present invention relates to contact lenses, and in particular, to contact lenses that provide a pleasant cooling sensation when worn. Background Technology
[0002] The cornea is the most nerve-dense tissue in the body and is stimulated exclusively by A-delta and C primary afferent fibers. C nerve fibers are not myelinated; A-delta fibers are slightly myelinated, but they lose their myelin sheath after entering the cornea, keeping it transparent. Therefore, for both types of nerve fibers, the nerve endings are exposed when they reach the squamous layer of the cornea. Receptors that detect temperature, chemistry, pain, and touch are located at these nerve endings.
[0003] Transient receptor potential cation channel subfamily M member 8 (TRPM8) is a protein channel that is a major molecular transducer of human cold sensation. A therapeutic composition containing an amount of TRPM8 agonist effective in increasing tears has been proposed for the treatment of dry eye disease (Belmonte et al., U.S. Patent No. 10,028,920).
[0004] N-(4-methoxyphenyl)-5-methyl-2-(1-methylethyl)cyclohexanecarboxamide (CAS No. 68489-09-8), known as WS12, is a synthetic menthol derivative that acts as a selective TRPM8 agonist. WS12 can be incorporated into silicone hydrogel contact lenses and can withstand autoclave sterilization without degradation or leaching into the packaging solution. These lenses can provide a cooling sensation, reduce lens dryness, and improve the wearer's comfort of wearing the lenses. However, some lens wearers experience stinging / burning upon initial insertion of the lenses (U.S. Patent Publication No. 2022 / 0350163). Although the stinging / burning may be temporary, it can prevent the wearer from using the contact lenses at all.
[0005] There is a desire to provide contact lenses that can provide a pleasant cooling sensation to wearers without causing stinging or burning upon insertion.
[0006] summation
[0007] The feature of the present invention is to provide a contact lens that releases a TRPM8 agent upon wear, thereby providing a pleasant cooling sensation without causing stinging or burning sensations in the insert.
[0008] A further feature of the present invention is to provide a cooling contact lens comprising a TRPM8 agonist that most contact lens wearers find more comfortable to wear than a lens made of the same material but without a TRPM8 antagonist, regardless of whether they experience symptoms of discomfort or dryness with their usual contact lenses.
[0009] Further features and benefits of the present invention will be described in part in the following description, and in part will be apparent from the description or can be learned through the practice of the invention. Objects and other benefits of the present invention will be realized and achieved through the elements and combinations specifically noted in the description and the appended claims.
[0010] To achieve these and other benefits, and according to the purpose of the present invention, the present invention relates to a contact lens comprising a certain amount of TRPM8 agonist releasedly attached to the lens to partially improve the comfort or desirability of the contact lens as embodied and broadly described herein, and a certain amount of TRPM8 antagonist delivered to the eye upon initial insertion of the contact lens to weaken the activity of the TRPM8 agonist during the initial wearing period. Brief explanation of the drawing
[0011] Fig. 1 This is a box plot showing the preference of symptomatic and asymptomatic contact lens wearers for WS12-emission contact lenses or control lenses 30 days after wearing the lenses. Specific details for implementing the invention
[0012] TRPM8 agonists have been found to improve end-of-day dryness and / or reduce CLDEQ-8 scores after 30 days of wear when embedded in and released from contact lenses. However, some subjects experience initial stinging / burning upon insertion, which decreases but may not disappear by the end of the 30-day period (see U.S. Patent Application Publication No. 2022 / 0350163).
[0013] TRPM8 agonist-release contact lenses that additionally deliver a fast-acting TRPM8 antagonist to the eye upon initial insertion reduce or eliminate the stinging / burning sensation caused by the release of the TRPM8 agonist. Therefore, by using TRPM8 antagonists in combination with TRPM8 agonists and utilizing their varying solubility and / or release characteristics, TRPM8 agonist-release contact lenses are provided that are comfortable to wear from initial insertion to the end of the day.
[0014] The present invention relates in part to contact lenses (e.g., hydrogel contact lenses), the use of contact lenses, and a method for manufacturing contact lenses. A TRPM8 agonist is present in and / or on the lens in an amount that improves the comfort of wearing the contact lens, which is released from the lens during wear. A TRPM8 antagonist is additionally present in and / or on the lens such that the TRPM8 antagonist is released from the lens during wear and / or initial insertion in an amount that prevents or reduces any stinging / burning sensation that a wearer may experience during initial contact lens wear, for example, within the first 30 minutes after the contact lens is first inserted into the eye.
[0015] The present invention relates to a non-wearing sterile contact lens that is partially immersed in a packaging solution and sealed in a package (e.g., a blister package). Preferred contact lenses, namely hydrogel contact lenses, are discussed below, but it should be understood that the present invention is applicable to other types of contact lenses.
[0016] A non-wearing hydrogel contact lens may comprise a) a polymeric lens body; b) a certain amount of at least one TRPM8 agonist releasedly attached to the polymeric lens body; and c) a certain amount of at least one TRPM8 antagonist releasedly attached to the polymeric lens body, present in a packaging solution, or both, may be essentially composed of, may be composed of, or may include.
[0017] As used herein, the term "TRPM8 agonist" refers to a compound that acts as a physiological coolant by activating TRPM8. The term "TRPM8 agonist" or "the above TRPM8 agonist" includes one or more such coolants.
[0018] Some examples of TRPM8 agents that can be loaded into polymeric lens bodies include 1,8-cineol (CAS No. 470-82-6), D-3263 (CAS No. 1008763-54-9), ethyl menthan carboxamide (CAS No. 39711-79-0), Evercool 180 (CAS No. 1187627-98-0), Evercool 190 (CAS No. 926913-58-8), Frescolat MGA (CAS No. 63187-91-7), Frescolat ML (CAS No. 59236-38-0), icilin (CAS No. 36945-98-9), and isopulegol (CAS No. 7786-67-6), methoxypropanediol (CAS No. 87061-04-9), methyl diisopropylpropionamide (CAS No. 5115-67-4), menthyl lactate (CAS No. 59259-38-0), piperitenone oxide (CAS No. 3564-96-3), p-mentan-3,8-diol (CAS No. 42822-86-6), WS12 (CAS No. 68489-09-8), WS-3 (CAS No. 39711-79-0), WS-5 (CAS No. 68489-14-5), or any mixture or combination thereof are included, but not limited thereto. These and other TRPM8 agonists are well known in the relevant art (see, for example, the literature [Leffingwell & Rowsell, Perfumer & Flavorist, Vol. 39, Mar. 2014, p. 34-44]).
[0019] In some examples, the TRPM8 agent is a menthol compound. As used herein, the term "menthol compound" refers to a compound of Formula 1:
[0020]
[0021] Here, X represents OH (thus, Formula 1 is menthol), or a substituent that is a TRPM8 agonist and thereby produces a menthol derivative acting as a physiological coolant. Examples of menthol compounds include, but are not limited to, menthol, l-menthol, menthoxypropanediol, WS-3, and WS12. Additional menthol compounds are well known and commercially available (see, e.g., U.S. Patent No. 10,028,920 and the literature [Gonzalez-Muniz et al., Int. J. Mol. Sci. (2019) 20, 2618]). References to specific compounds herein are intended to include all enantiomer forms and pharmaceutically acceptable salts of the compound unless otherwise indicated in the context.
[0022] TRPM8 agonists can be attached to contact lenses in a releaseable manner, so that when the lenses are worn, the TRPM8 agonists are released from the lenses to provide a pleasant cooling sensation to the wearer and / or increase the wearer's comfort. In the field of ophthalmology, various methods for determining the improvement of contact lens wearing comfort are well known (e.g., reduction of dryness symptoms in the contact lens wearer, and / or increase in the comfortable lens wearing time in the contact lens wearer, and / or increase in the tear meniscus height in the contact lens wearer, and / or decrease in the CLDEQ-8 score in the contact lens wearer, and / or decrease in the VAS score in the contact lens wearer), and are further described below.
[0023] The amount of compound "emissionably attached" to the polymeric lens body used herein refers to the amount of compound that can be extracted from the contact lens using the ethanol extraction method described in Example 1 below. The amount of TRPM8 agent emissionably attached to the polymeric lens body may be about 0.10 μg to 100 μg or more, or about 0.25 μg to 50 μg or more, or about 0.5 μg to 25 μg, or any other amount greater than or less than any of the ranges presented herein. In certain examples, the TRPM8 agent is a menthol compound. In further specific examples, the TRPM8 agent present in the polymeric lens body is WS12, and the amount of WS12 emissionably attached to the polymeric lens body is about 0.25 μg to about 10.0 μg, preferably about 0.5 μg to 5 μg.
[0024] TRPM8 agonists 0.01 μg to 10 μg or more of TRPM8 agonists after 1 hour In a test tube It may be present in a polymeric lens body in an amount that causes emission. In a polymeric lens body used herein at a given point in time or over a series of points in time In a test tube The amount of TRPM8 agonist released (i.e., the "release profile") is a release medium consisting of 25 volume% ethanol (EtOH) in phosphate-buffered saline (PBS) (hereinafter " In a test tube Emission medium") and the method described in Example 3 (hereinafter " In a test tube It is determined using the release method"). TRPM8 agonist after 1 hour In a test tubeThe release may be 0.01 μg to 10 μg, or 0.02 μg to 10 μg, or 0.05 μg to 10 μg, or 0.075 μg to 10 μg, or 0.1 μg to 10 μg, or 0.5 μg to 10 μg, or 0.75 μg to 10 μg, or 1 μg to 10 μg, or 2 μg to 10 μg, or 3 μg to 10 μg, or 5 μg to 10 μg.
[0025] TRPM8 agonists may be present in the polymeric lens body in an amount that provides sustained release of TRPM8 agonists from the contact lens for at least 9 hours. Sustained release for 9 hours occurs when the cumulative amount of TRPM8 agonists released from the polymeric lens body at the 12-hour mark is greater than the cumulative amount of TRPM8 agonists released from the polymeric lens body at the 9-hour mark. In a test tube This is demonstrated by the release method. Similarly, sustained release of TRPM8 agonists for at least 12 hours is demonstrated by the fact that the cumulative amount of TRPM8 agonists released from the polymeric lens body at the 16-hour mark is greater than that at the 12-hour mark. In one example, the TRPM8 agonist present in the polymeric lens body is WS12, and after 1 hour In a test tube The amount of released WS12 is 0.01 μg to 0.20 μg. In another example, the TRPM8 agent present in the polymeric lens body is WS12, and the release of WS12 continues for at least 6 hours, preferably at least 9 hours, more preferably at least 12 hours.
[0026] The contact lens further comprises at least one TRPM8 antagonist that is releaseably attached to the polymeric lens body or is present in the packaging solution, or is releaseably attached to the polymeric lens body and is present in the packaging solution. TRPM8 may attenuate the activity of TRPM8 agonists released from the lens during the initial wear period. As used herein, the term "TRPM8 antagonist" or "the TRPM8 antagonist" comprises one TRPM8 antagonist or more than one TRPM8 antagonist used together. Exemplary TRPM8 antagonists include AMG-333 (CAS No. 1416799-28-4), AMG-2850 (CAS No. 1470018-52-0), AMG-8788 (CAS No. 1159996-43-6), AMG-9090 (CAS No. 118215-82-0), AMG-9678 (CAS No. 1159997-27-9), AMTB: N -(3-aminopropyl)-2-[(3-methylphenyl)methoxy]- N -(2-thienylmethyl)benzamide hydrochloride (CAS No. 926023-82-7), BCTC (CAS No. 393514-24-4), cannabidivarin (CAS No. 24274-48-4), M8-An: (See reference [Patel et al., J Pharmacol Exp Ther. 2014 Apr; 349(1):47-55]), M8-B (CAS No. 883976-12-3), PF 05105679 (CAS No. 1398583-31-7), RN-1747 (CAS No. 1024448-59-6), RQ 00203078 (CAS No. 1254205-52-1), TC-I 2000 (CAS No. 1159996-20-9), TC-I 2014 (CAS No. 1221349-53-6) or any mixture or combination thereof are included. These and other TRPM8 antagonists are well known in the relevant technical field (e.g., see literature [Gavva et al., Mol Pain, 2012 May 9:8:36]; and [Beccari et al., Nature.com, Scientific Reports, 2017, 7:10999]).
[0027] The amount of TRPM8 antagonist used in the contact lens and / or packaging solution is effective in providing a reduction in stinging or discomfort during the first 30 minutes after wearing TRPM8 agonist-releasing lenses compared to control lenses that are otherwise identical but lack the TRPM8 antagonist. This "effective amount" of TRPM8 antagonist can be determined by routine clinical studies in which subjects wear a test lens (i.e., a lens containing both a TRPM8 agonist and a TRPM8 antagonist) and a control lens on opposite sides for 30 minutes. The reduction in initial discomfort, such as within 30 minutes of lens insertion, can be demonstrated using a validated Visual Analog Scale (VAS), where the lens wearer records perceived discomfort on a linear scale, with the left end of the scale indicating "no discomfort" and the right end indicating "most discomfort" (see reference [Delgado et al. J Am Acad Orthop Surg Glob Res Rev. 2018 Mar; 2(3): e088]). When wearing lenses containing both TRPM8 agonists and TRPM8 antagonists, compared to lenses that do not contain TRPM8 antagonists but are otherwise identical, an improvement of at least 1 on a scale of 1 to 10 (i.e., corresponding to 1 cm on a standard paper-based 10-cm line scale) demonstrates a significant reduction in discomfort. In some cases, the improvement in the VAS score is at least 2, at least 3, or at least 4.
[0028] In some examples, the TRPM8 antagonist is releasedly attached to the polymeric lens body in an amount of about 0.10 μg to 100 μg or more, or about 0.25 μg to 50 μg or more, or about 0.5 μg to 25 μg, or other amounts greater than or less than any of the ranges presented herein. In some examples, the TRPM8 antagonist may be additionally or alternatively present in the packaging solution in an amount of about 0.1 μg / ml to about 100 μg / ml or about 1 μg / ml to about 10 μg / ml.
[0029] As an option, a TRPM8 agonist may be loaded onto or within a contact lens, and then a TRPM8 antagonist may be loaded onto or within the same lens. As an example, a TRPM8 agonist may be loaded into the contact lens during a solvent extraction step, and subsequently, a TRPM8 antagonist is loaded into the contact lens during a hydration step. As an option, the TRPM8 antagonist is at least partially soluble in the packaging solution, so that when the TRPM8 antagonist is loaded onto the contact lens and subsequently placed in the packaging solution, at least a portion of the TRPM8 antagonist leaches from the lens into the packaging solution.
[0030] As an option, the TRPM8 antagonist may be dissolved in the packaging solution. As an option, when a lens is placed in a packaging solution containing the TRPM8 antagonist, at least a portion of the TRPM8 antagonist is distributed into the lens and attached to the polymeric lens body in a releaseable manner. Thus, in some examples, both the contact lens and the packaging solution contain the TRPM8 antagonist.
[0031] In examples where at least a portion of the TRPM8 antagonist is present in the contact lens packaging solution, the contact lens may take in a portion of the packaging solution when the lens is removed from the package and placed in the eye. In this manner, the TRPM8 antagonist present in the packaging solution is immediately available to block TRPM8 and attenuate the action of the TRPM8 agonist during the initial period of contact lens wear. In some examples, the TRPM8 antagonist is releasedably attached to the lens and is released from the contact lens before or simultaneously with the release of the TRPM8 agonist. In some examples, the TRPM8 antagonist is not only present in the packaging solution but is also releasedably attached to the contact lens.
[0032] In some examples, the TRPM8 antagonist is at least minimally soluble in water at room temperature (hereinafter referred to herein as "water-soluble") and has greater water solubility than the TRPM8 agonist. In one example, the TRPM8 antagonist is water-soluble and the TRPM8 agonist is insoluble in water. In one example, the TRPM8 antagonist is at least partially soluble in the packaging solution and the TRPM8 agonist is insoluble in the packaging solution.
[0033] In one example, Example 3's In a test tube As determined using the release method, the amount of TRPM8 antagonist released from the lens at the 2-hour mark is less than 150% of the amount of TRPM8 antagonist released from the lens at the 1-hour mark. That is, the amount of TRPM8 antagonist released from the lens between the 1-hour and 2-hour mark does not exceed 50% of the amount released from the lens during the first hour, and preferably does not exceed 20% of the amount released from the lens during the first hour.
[0034] In some examples, the ratio of TRPM8 antagonist to TRPM8 agonist released from the lens during the first hour is of Example 3. In a test tubeAs determined by the release method, it is at least 2 to 1, or at least 5 to 1, or at least 10 to 1. In some examples, the TRPM8 agonist is WS12 and the TRPM8 antagonist is M8-An, and In a test tube In the emission method, the ratio of M8-An to WS12 emitted from the lens during the first time is at least 2 to 1, or at least 5 to 1, or at least 10 to 1. In some examples, the lens is In a test tube In the release method, 0.1 μg to 0.5 μg of WS12 and 1.0 μg to 50 μg of M8-An are released during the first hour.
[0035] As an option, the contact lens sustains the release of a TRPM8 agonist for at least 9 hours, preferably at least 12 hours, and sustains the release of a TRPM8 antagonist for 3 hours or less, preferably 2 hours or less.
[0036] As an example, a contact lens comprises a polymeric lens body that is a reaction product of a polymerizable composition comprising at least one siloxane monomer and at least one hydrophilic monomer and / or at least one hydrophilic polymer. Conveniently, as described in more detail below, a cured polymeric lens body for silicone hydrogel may be extracted in an extraction solvent containing a TRPM8 agent such as WS12, which allows a desired amount of TRPM8 agent (e.g., WS12) to be attached to the polymeric lens body. Alternatively, or additionally, a TRPM8 agent (e.g., WS12) may be added to the polymerizable composition. The TRPM8 agent (e.g., WS12) may be attached to the polymeric lens body by hydrophobic interactions and / or physically captured by the polymer network of the polymeric lens body.
[0037] The polymeric lens body may comprise any hydrogel material suitable for use as a contact lens material. Silicone hydrogel materials for contact lenses are typically formed by curing a polymerizable composition (i.e., a monomer mixture) comprising at least one siloxane monomer and at least one hydrophilic monomer or at least one hydrophilic polymer, or a combination thereof. As used herein, the term “siloxane monomer” refers to any molecule containing at least one Si-O group and at least one polymerizable functional group. Siloxane monomers used in contact lens compositions are well known in the art (see, for example, U.S. Patent No. 8,658,747 and U.S. Patent No. 6,867,245). (All patents and publications mentioned herein and throughout the text are incorporated by reference in their entirety.) In some examples, the polymerizable composition comprises a total amount of siloxane monomers of at least 10 wt%, 20 wt%, or 30 wt% to about 40 wt%, 50 wt%, 60 wt%, or 70 wt% or less. Unless otherwise specified, as used herein, a given weight percentage (wt%) of a component of a polymerizable composition is relative to the total weight of all polymerizable components and IPN polymers in the polymerizable composition (as further described below). The weight of the polymerizable composition contributed by components such as diluents that are not incorporated into the final contact lens product is not included in the weight% calculation.
[0038] In certain examples, the polymerizable composition comprises a hydrophilic vinyl monomer. As used herein, "hydrophilic vinyl monomer" is any siloxane-free (i.e., not containing Si-O groups) hydrophilic monomer having a polymerizable carbon-carbon double bond (i.e., vinyl group) present in the molecular structure that is not part of an acrylic group, wherein the carbon-carbon double bond of the vinyl group is less reactive than the carbon-carbon double bond present in the polymerizable methacrylate group under free radical polymerization. As used herein, the term "acrylic group" refers to a polymerizable group present in acrylates, methacrylates, acrylamides, etc. Thus, as used herein, carbon-carbon double bonds are present in acrylates and methacrylates, but these polymerizable groups are not considered to be vinyl groups. Additionally, as used herein, a monomer is "hydrophilic" if at least 50 g of the monomer is completely dissolved in 1 liter of water at 20°C (i.e., ~5% soluble in water) as visually determined using the standard shake flask method. In various examples, the hydrophilic vinyl monomer is N-vinyl-N-methylacetamide (VMA), or N-vinylpyrrolidone (NVP), or 1,4-butanediol vinyl ether (BVE), or ethylene glycol vinyl ether (EGVE), or diethylene glycol vinyl ether (DEGVE), or any combination thereof. In one example, the polymerizable composition comprises at least 10 wt%, 15 wt%, 20 wt%, or 25 wt% to about 45 wt%, 60 wt%, or 75 wt% or less of the hydrophilic vinyl monomer. As used herein, a given weight percentage of a specific class of components (e.g., hydrophilic vinyl monomers, siloxane monomers, etc.) in a polymerizable composition is equal to the sum of the weight percentages of each component in the composition belonging to that class.Accordingly, for example, a polymerizable composition comprising 5 wt% BVE and 25 wt% NVP and not comprising other hydrophilic vinyl monomers is said to comprise 30 wt% of hydrophilic vinyl monomer. In one example, the hydrophilic vinyl monomer is a vinyl amide monomer. Exemplary hydrophilic vinyl amide monomers are VMA and NVP. In a specific example, the polymerizable composition comprises at least 25 wt% of vinyl amide monomer. In further specific examples, the polymerizable composition comprises about 25 wt% to about 75 wt% or less of VMA or NVP, or a combination thereof. Additional hydrophilic monomers that may be included in the polymerizable composition are N,N-dimethylacrylamide (DMA), 2-hydroxyethyl methacrylate (HEMA), ethoxyethyl methacrylamide (EOEMA), ethylene glycol methyl ether methacrylate (EGMA), and combinations thereof.
[0039] In addition to or as an alternative to the hydrophilic monomer, the polymerizable composition may include a non-polymerizable hydrophilic polymer, which forms a polymeric lens body comprising an interpenetrating polymer network (IPN) in which the non-polymerizable hydrophilic polymer interpenetrates the silicone hydrogel polymer matrix. In this example, the non-polymerizable hydrophilic polymer is referred to as an IPN polymer that acts as an internal wetting agent in the contact lens. On the other hand, polymer chains within the silicone hydrogel network formed by the polymerization of the monomers present in the polymerizable composition are not considered to be IPN polymers. The IPN polymer may be, for example, a high molecular weight hydrophilic polymer of about 50,000 to about 500,000 daltons. In certain examples, the IPN polymer is polyvinylpyrrolidone (PVP). In other examples, the polymerizable composition does not substantially contain polyvinylpyrrolidone or other IPN polymers.
[0040] As an option, one or more non-silicon-containing hydrophobic monomers may be present as part of the polymerizable composition. The hydrophobic monomer can be understood as any monomer in which 50 grams of the monomer is not visibly completely soluble in 1 liter of water at 20°C using the standard shake flask method. Examples of suitable hydrophobic monomers include methyl acrylate, or ethyl acrylate, or propyl acrylate, or isopropyl acrylate, or cyclohexyl acrylate, or 2-ethylhexyl acrylate, or methyl methacrylate (MMA), or ethyl methacrylate, or propyl methacrylate, or butyl acrylate, or 2-hydroxybutyl methacrylate, or vinyl acetate, or vinyl propionate, or vinyl butyrate, or vinyl valerate, styrene, or chloroprene, or vinyl chloride, or vinylidene chloride, or acrylonitrile, or 1-butene, or butadiene, or methacrylonitrile, or vinyl toluene, or vinyl ethyl ether, or perfluorohexylethylthiocarbonylaminoethyl methacrylate, or isobornyl methacrylate (IBM), or trifluoroethyl methacrylate, or hexafluoroisopropyl methacrylate, or tetrafluoropropyl Methacrylates, or hexafluorobutyl methacrylate, or any combination thereof are included.
[0041] When used, the hydrophobic monomer may be present in the reaction product of the polymerizable composition in an amount of 1% to about 30% by weight, for example, 1% to 25% by weight, 1% to 20% by weight, 1% to 15% by weight, 2% to 20% by weight, 3% to 20% by weight, 5% to 20% by weight, 5% to 15% by weight, and 1% to 10% by weight, based on the total weight of the polymerizable composition.
[0042] The polymerizable composition may additionally comprise at least one crosslinking agent. As used herein, the term "crosslinking agent" is a molecule having at least two polymerizable groups. Thus, the crosslinking agent can react with two or more functional groups on the polymer chains to bridge one polymer to another. The crosslinking agent may comprise an acrylic group or a vinyl group, or both an acrylic group and a vinyl group. In certain examples, the crosslinking agent does not contain a siloxane moiety; that is, it is a non-siloxane crosslinking agent. Various crosslinking agents suitable for use in silicone hydrogel polymerizable compositions are known in the art (see, for example, U.S. Patent No. 8,231,218, incorporated herein by reference). Examples of suitable crosslinking agents include, without limitation, lower alkylene glycol di(meth)acrylates, e.g., triethylene glycol dimethacrylate, diethylene glycol dimethacrylate, poly(lower alkylene) glycol di(meth)acrylate and lower alkylene di(meth)acrylate; divinyl ethers, e.g., triethylene glycol divinyl ether, diethylene glycol divinyl ether, 1,4-butanediol divinyl ether and 1,4-cyclohexanedimethanol divinyl ether; divinyl sulfone; di- and trivinylbenzene; trimethylolpropane tri(meth)acrylate; pentaerythritol tetra(meth)acrylate; bisphenol A di(meth)acrylate; methylenebis(meth)acrylamide; trialyl phthalate; 1,3-bis(3-methacryloxypropyl)tetramethyldisiloxane; Diallyl phthalate; and combinations thereof are included.
[0043] As would be understood by a person skilled in the art, the polymerizable composition may include additional polymerizable or non-polymerizable components typically used in contact lens formulations, such as one or more of polymerization initiators, UV absorbers, tinting agents, oxygen scavengers, and chain transfer agents. In some examples, the polymerizable composition may include an organic diluent in an amount to prevent or minimize phase separation between the hydrophilic and hydrophobic components of the polymerizable composition, thereby obtaining an optically clear lens. Diluents typically used in contact lens formulations include hexanol, ethanol, and / or other primary, secondary, or tertiary alcohols. In other examples, the polymerizable composition does not contain or substantially does not contain an organic diluent (e.g., less than 500 ppm). In these examples, using a siloxane monomer containing a hydrophilic moiety, such as a polyethylene oxide group, a pendant hydroxyl group, or other hydrophilic groups, may eliminate the need for the polymerizable composition to contain a diluent. Non-limiting examples of such components and additional components that may be included in a polymerizable composition are provided in U.S. Patent No. 8,231,218.
[0044] Non-limiting examples of silicone hydrogels that can be used include comfilcon A, fanfilcon A, riofilcon A, stenfilcon A, senofilcon A, senofilcon C, somofilcon A, narafilcon A, delefilcon A, narafilcon A, lotrafilcon A, lotrafilcon B, balafilcon A, samfilcon A, gallyfilcon A, and asmofilcon A.
[0045] A specific example of the hydrogel contact lens of the present invention is based on a polymerizable composition comprising 25% to 55% by weight of siloxane monomer(s), 30% to 55% by weight of a vinyl monomer selected from NVP, VMA, or a combination thereof, optionally about 1% to about 20% by weight of a hydrophilic monomer selected from N,N-dimethylacrylamide (DMA), 2-hydroxyethyl methacrylate (HEMA), ethoxyethyl methacrylamide (EOEMA), or ethylene glycol methyl ether methacrylate (EGMA), or any combination thereof, and optionally about 1% to about 20% by weight of a hydrophobic monomer selected from methyl methacrylate (MMA), isobornyl methacrylate (IBM), or 2-hydroxybutyl methacrylate (HOB), or any combination thereof. The silicone hydrogel material prepared from this particular embodiment of the polymerizable composition comprises stenfilcon A, comfilcon A, lyophilcon A, somofilcon A, panfilcon A, and enfilcon A. In additional examples, the polymerizable composition described above comprises siloxane monomers of stenfilcon A, specifically a first siloxane monomer having a structure represented by formula (I), and a second siloxane monomer having a structure represented by formula (II):
[0046]
[0047] Chemical formula (I)
[0048]
[0049] Chemical formula (II).
[0050] The contact lens of the present invention can be manufactured using conventional methods. As an example, a polymerizable composition for a hydrogel composition is dispensed into a female mold member having a concave surface defining the front surface of the contact lens. A male mold member having a convex surface, i.e., a corneal-contact surface, defining the rear surface of the contact lens is combined with the female mold member to form a contact lens mold assembly in which curing conditions, such as UV or thermal curing conditions, are applied, thereby forming the curable composition into a polymeric lens body. The female and male mold members may be non-polar molds or polar molds. The mold assembly is disassembled (i.e., demolded), the polymeric lens body is removed from the mold, and unreacted components are extracted from the lens body using an organic solvent.
[0051] Conveniently, a TRPM8 agent such as WS12 can be loaded onto the polymeric lens during the extraction step. Typically, after curing, the polymeric lens body swells in an extraction solvent containing a TRPM8 agent (e.g., WS12). When the extracted polymeric lens body is subsequently placed in a hydration solution such as deionized water, the extraction solvent is removed, and the TRPM8 agent (e.g., WS12) remains attached to the polymeric lens body.
[0052] As an example, the extraction and hydration process may comprise at least one extraction step in denatured ethanol (EtOH), followed by an extraction step comprising a mixture of EtOH and water, such as about 10% to 95% EtOH in water, e.g., about 30% to 80% EtOH in water, followed by at least one hydration step in deionized water, wherein each extraction and hydration step may be sustained for about 15 minutes to about 3 hours at a temperature of about 20°C to about 30°C. Any extraction solvent may be used as an uploading solution for a TRPM8 agent (e.g., WS12). In one example, the concentration of the TRPM8 agent (e.g., WS12) in the extraction solvent is about 1.0 μg / ml to about 4.0 μg / ml (i.e., 1 ppm to about 4 ppm). In one example, the initial extraction solvent is EtOH and the second extraction solvent comprises a mixture of 30% to 80% EtOH in water and 1 ppm to 4 ppm of TRPM8 agent (e.g., WS12).
[0053] As part of the present invention, a contact lens may be sealed in a contact lens package. The packaging solution sealed within the contact lens package may be any conventional contact-lens compatible solution. In one example, the packaging solution comprises, consists of, or essentially consists of an aqueous solution of a buffer and / or tonicity agent. In another example, the packaging solution contains one or more additional agents, such as an additional antimicrobial agent and / or comfort agent and / or hydrophilic polymer and / or surfactant and / or other beneficial agents. In some examples, the packaging solution may comprise a polysaccharide (e.g., hyaluronic acid, hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, etc.) or other high molecular weight polymers such as polyvinylpyrrolidone, which is commonly used as a comfort polymer or thickener in ophthalmic solutions and contact lens packaging solutions. In another example, the packaging solution may contain an ophthalmic drug. The packaging solution may have a pH within the range of about 6.8 or 7.0 to about 7.8 or 8.0 or less. In one example, the packaging solution contains a phosphate buffer or a borate buffer. In yet another example, the packaging solution contains an osmotic regulator selected from sodium chloride or sorbitol in an amount that maintains the osmotic pressure within the range of about 200 to 400 mOsm / kg, typically about 270 mOsm / kg to about 310 mOsm / kg or less.
[0054] With respect to a contact lens package, the package may include, or may include, a plastic base member comprising a cavity configured to hold the contact lens and the packaging solution, and a flange area extending outwardly around the cavity. A removable foil is attached to the flange area to provide a liquid-tight seal. The removable foil may be sealed by any conventional means, such as heat sealing or gluing. Such contact lens packages, generally referred to as "blister packs," are well known in the art (see, for example, U.S. Patent No. 7,426,993). The sealed package may be sterilized by sterilizing an amount of radiation containing heat or steam, for example, by autoclaving, or by gamma radiation, e-beam radiation, ultraviolet radiation, etc. In certain examples, the packaged contact lens is sterilized by autoclaving.
[0055] The final product may be a sterile, packaged contact lens with ophthalmologically acceptable surface wettability (e.g., a silicone hydrogel contact lens).
[0056] In some examples, the TRPM8 agent is loaded onto the polymeric lens body, for example, during the ethanol extraction step, and is not substantially leached from the polymeric lens body after the lens is placed in the packaging solution. Thus, the packaging solution in which the contact lens is immersed becomes "substantially free" of the TRPM8 agent before, or immediately after, or after 1 day, or after 30 days, or after 60 days, or after 120 days, which means that any menthol compound present in the packaging solution is below the detection limit determined by HPLC.
[0057] The following examples illustrate specific aspects and advantages of the present invention, and it should be understood that the present invention is not limited thereto.
[0058] Example 1. Preparation of WS12-Emitting Contact Lenses
[0059] Silicone hydrogel contact lenses were prepared by curing the Stenfilcon A formulation in a contact lens mold. The cured Stenfilcon A was removed from the mold and extracted by immersing it in ethanol (EtOH) containing WS12 (Tocris Bioscience) at the loading concentrations presented in Table I for 215 minutes. The lenses were removed from the EtOH and washed with DI water for approximately 6 minutes, followed by two DI water changes for approximately 30 minutes each. The lenses were transferred to a 6 mL glass vial containing 3 mL of phosphate-buffered saline (0.78 wt% NaCl, 0.05 wt% sodium phosphate monobasic, and 0.36 wt% sodium phosphate dibasic) at pH 7.5, referred to herein as PBS. The vial was sealed and autoclaved.
[0060] Extraction method: Each autoclaved lens was transferred to a vial containing 3 ml of EtOH and stored overnight in a 150 rpm shaker at room temperature to extract WS12 from the lens. The EtOH extracts and PBS from the autoclaved lenses were submitted for analysis by HPLC (detection wavelength = 250 nm) according to calibration standards to determine the average amount of WS12 loaded in each (n=5) and whether WS12 leached from the lens during autoclaving. The results are presented in Table 1.
[0061] Table 1.
[0062]
[0063] Silicone hydrogel contact lenses were prepared by curing the formulation of Comfilcon A in a contact lens mold and performing the same extraction, hydration, and autoclave procedures as described above on lenses made of Comfilcon A, except that a single WS12 concentration of 15 μg / mL was used in the ethanol extraction step. Lenses (Lens D) were submitted for HPLC analysis of WS12 content and were shown to have an average WS12 absorption of 1.04 μg / lens.
[0064] Example 2. Emission of WS12 from contact lenses during lens wear
[0065] Lens B of Example 1 was worn by human subjects for 1 hour, 3 hours, and 6 hours (n=2 for each time point). At the end of each lens wearing period, the lens was extracted from EtOH using the method described in Example 1. The extract was submitted for HPLC analysis to determine the residual amount of WS12 remaining in the lens and to calculate the amount of WS12 released during wear. The average amount and percentage of WS12 released during lens wear are presented in Table 2.
[0066] Table 2.
[0067]
[0068] Example 3. In-tube release method
[0069] contact lenses containing TRPM8 agents In a test tubeIn the release method, remove the lenses from the container and shake each lens to remove excess packaging solution. Transfer each lens (n=3 for each time point) to a 6 mL glass vial containing 3 mL of 25 vol% ethanol in PBS at 35°C (EtOH release medium). Place the vial in a shaker at 125 rpm in a 35°C incubator. At the 30-minute and 1-hour sample time points (i.e., the 30-minute and 1-hour time point vials, respectively), remove 2.5 mL of EtOH release medium and submit for HPLC analysis. At the 1-hour time point and subsequent time points (i.e., at 2, 3, 6, 9, 12, and 16 hours), remove 2.5 mL of EtOH release medium from each remaining vial and add 2.5 mL of fresh EtOH release medium back into each vial. Calculate the cumulative WS12 release amount at each time point. For example, the 3-hour mark is the sum of the average amounts of WS12 detected in the emission medium obtained at the 1-hour, 2-hour, and 3-hour marks.
[0070] As stated above In a test tube As for the emission method, WS12 from contact lenses that closely matches the WS12 emission from contact lenses worn on the eye, as presented in Table 3 compared with Table 2. In a test tube Release is obtained.
[0071] Table 3
[0072]
[0073] contact lenses containing TRPM8 antagonists In a test tube The release method is the same as described above for TRPM8 agonists, except that the sample time points are 10 minutes, 20 minutes, 30 minutes, 1 hour, 3 hours, and 5 hours.
[0074] Example 4. Dose-escalating, 1-day clinical study of WS12-emission contact lenses
[0075] Two subjects were recruited for a study evaluating all three loading concentrations of Example 1. Each subject was exposed to lenses A, B, and C of Example 1 by wearing them on opposite sides of one eye for 30 minutes, respectively. On the first day of the study, subjects were exposed to wearing lenses B and C on opposite sides, and then on a separate day, to wearing lenses B and A on opposite sides. In the case of lens C, one subject experienced stinging, while the other experienced a cold sensation. In the case of lens B, both subjects experienced mild cold / tingling for approximately one hour. Lens A induced a brief cold / wetting sensation in the subjects. Lens B was selected for further evaluation.
[0076] Example 5. 30-Day Clinical Study of WS12-Emitting Contact Lenses
[0077] Thirty-three subjects were enrolled in a two-sided, randomized, crossover double-blind study for one month, where the subjects wore either Lens B of Example 1 (Trial) or MyDay® brand (Control) contact lenses for one month, respectively. Young et al. ( supra The subjects were classified as symptomatic (S) or asymptomatic (A) contact lens wearers using the classification system described in Table 4, which adopted the classification system proposed by ).
[0078] Table 4
[0079]
[0080] Sixteen of the subjects were classified as symptomatic contact lens wearers, reporting a rating of 2 or higher on a 5-point scale for the intensity of contact lens dryness / discomfort and a rating of "occasionally, often, or always" for the frequency of contact lens dryness / discomfort. Seventeen of the subjects were classified as asymptomatic contact lens wearers, reporting a rating of 0 or 1 on a 5-point scale for the intensity of contact lens dryness / discomfort and a rating of "rarely or never" for the frequency of contact lens dryness / discomfort.
[0081] After a 3–7 day cleaning period while the subjects wore their usual lenses, a second type of lens in a random order (i.e., Example 1 (test) or MyDay® brand (control) contact lenses) was worn for 1 month. Comfort, dryness, cold sensation, and pleasantness, as well as CLDEQ-8 score ratings, were monitored (reference [Chalmers et al., Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8) and opinion of contact lens performance. See Optom Vis Sci 2012; 89(10):1435-1442].).
[0082] At the 1-week mark, the test lens was rated as significantly less comfortable upon insertion than the control lens, but this difference decreased after 1 month of wear. This change may be attributed to a reduction in cold sensation resulting from sensory adaptation in subjects wearing the test lens. There was no significant difference in the assessment of overall comfort between the test lens and the control lens at the 1-week or 1-month mark. However, twice as many subjects reported increased comfort with the test lens compared to the control lens after 1 month of wear. Compared to the control lens, the assessment of overall dryness was significantly improved (i.e., lowered) for the test lens at both 1 week and 1 month. Tear meniscus height was measured using a Visante OCT (Carl Zeiss Meditec Inc., Dublin, California) and increased significantly after 1 month of wearing the test lens compared to the control lens. The CLDEQ-8 score was significantly lower after 1 month of wearing the test lens compared to the control lens. There were statistically significant differences among symptomatic subjects. One month after wearing the lenses, among 33 subjects, 19 (58%) preferred the test lenses, 11 (33%) preferred the control lenses, and 3 (9%) reported no preference. Among 16 symptomatic subjects, 11 (69%) preferred the test lenses, and 5 (31%) preferred the control lenses. The results are shown in Figure 1.
[0083] Example 6. M8-B packaging solution.
[0084] Contact lenses were prepared from Stenfilcon A as described in Example 1 above, except that the ethanol in the extraction step did not contain WS12 and the PBS used for lens packaging contained 50 μg / ml M8-B.HCl (Cayman Chemical; CAS No. 883976-12-3). The packaged lenses were autoclaved or left at room temperature. After autoclaving, the lenses were transferred to individual vials containing 3 ml of EtOH for overnight extraction as described in Example 1 above. EtOH extracts and packaging solutions (Pkg. Soln.) from both the autoclaved lenses (with AC) and the non-autoclaved lenses (without AC) were submitted for analysis by HPLC (detection wavelength = 245 nm) against a calibration standard. The results are presented in Table 5.
[0085] Table 5
[0086]
[0087] Example 7. M8-An emission profile
[0088] Lenses were manufactured from Stenfilcon A and packaged in contact lens blister packages containing 1.2 mL of PBS containing 5 μg / ml, 10 μg / ml, or 20 μg / ml of M8-An (EMD Millipore Cat. No. 530617). The vials were autoclaved, and the loading amount of M8-An contained in the autoclaved lenses was determined using the ethanol extraction method of Example 1.
[0089] A contact lens containing a TRPM8 antagonist described in Example 3 above In a test tube M8-An using the release method In a test tube The emission profile was tested. The detection wavelength for HPLC analysis was 275 nm. The results are presented in Table 6.
[0090] Table 6.
[0091]
[0092] The experiment was repeated using a WS12-emitting Stenfieldcon A lens. M8-An In a test tube The emission profile was substantially identical to that of a lens not containing WS12. Similarly, WS12 from these lenses In a test tube The release profile was substantially the same as the release profile from the WS12-loaded Stenfilcon A lens packaged in PBS without M8-An, which indicates that the presence of both TRPM8 agonists and TRPM8 antagonists does not affect the release profiles of the two compounds.
[0093] The disclosures of this application refer to specific exemplary examples, but it should be understood that these examples are presented as examples and not as limitations. The intent of the foregoing detailed description is to discuss exemplary examples, but to be interpreted as encompassing all variations, alternatives, and equivalents of the examples that may fall within the spirit and scope of the invention as defined by additional disclosures.
[0094] References to “examples,” “specific examples,” “aspects,” “moderations,” or similar phrases herein are intended to introduce (depending on the context) features or characteristics of a WS12-emitting hydrogel contact lens or its components, a sealed contact lens package or its components, or a method for manufacturing a WS12-emitting hydrogel contact lens, which may be combined with any combination of previously or subsequently described examples, aspects, or embodiments (i.e., features), unless specific combinations of features are mutually exclusive or otherwise indicated by the context. Additionally, the singular form used herein includes multiple references (e.g., at least one) unless otherwise clearly indicated by the context. Thus, for example, a reference to “contact lens” includes not only a single lens but also two or more identical or different lenses.
[0095] The entire contents of all references cited in this disclosure are incorporated herein by reference, unless otherwise conflicted with this disclosure.
[0096] The present invention may include any combination of the various features or embodiments described in the claims above and / or below, as specified in sentences and / or paragraphs. Any combination of features disclosed herein is considered part of the present invention, and no limitation is intended with respect to the features that can be combined.
[0097] Other embodiments of the present invention will be apparent to those skilled in the art by considering the specification disclosed herein and the practice of the invention. The specification and embodiments are to be regarded merely as examples, and the true scope and spirit of the invention are intended to be indicated by the following claims and their equivalents.
Claims
Claim 1 (a) a packaging solution; and (b) a sealed contact lens package comprising a polymeric lens body immersed in the packaging solution, wherein a certain amount of TRPM8 agonist is releaseably attached to the polymeric lens body, and wherein a TRPM8 antagonist is present in the packaging solution or releaseably attached to the polymeric lens body, or present in the packaging solution and releaseably attached to the polymeric lens body. Claim 2 A sealed contact lens package according to claim 1, wherein the TRPM8 antagonist is M8-An. Claim 3 A sealed contact lens package according to claim 1, wherein the TRPM8 antagonist is AMTB. Claim 4 A sealed contact lens package according to any one of claims 1 to 3, wherein the TRPM8 agent is a menthol compound. Claim 5 In paragraph 4, a sealed contact lens package in which the menthol compound is WS12. Claim 6 A sealed contact lens package according to claim 5, wherein the amount of WS12 extrudably attached to a polymeric lens body is 0.25 μg to 10 μg. Claim 7 A sealed contact lens package according to claim 5, wherein the amount of WS12 releasedly attached to a polymeric lens body is 0.5 μg to 5 μg. Claim 8 In any one of paragraphs 1 to 3, the contact lens is composed of 25 volume% EtOH in PBS. In a test tube A sealed contact lens package that sustains the release of a TRPM8 agonist in a release medium for at least 6 hours. Claim 9 In any one of claims 1 to 3, a TRPM8 antagonist is releasedly attached to a polymeric lens body, wherein the contact lens is composed of 25 volume% EtOH in PBS. In a test tube A sealed contact lens package that releases at least 90 weight percent of a TRPM8 antagonist from a polymeric lens body within 3 hours in a release medium. Claim 10 A sealed contact lens package according to any one of claims 1 to 3, wherein the packaging solution substantially does not contain a TRPM8 agent. Claim 11 A sealed contact lens package according to any one of claims 1 to 3, wherein the TRPM8 antagonist is at least partially soluble in the packaging solution and the TRPM8 agonist is insoluble in the packaging solution. Claim 12 A sealed contact lens package according to any one of claims 1 to 3, wherein the polymeric lens body comprises a silicone hydrogel. Claim 13 A sealed contact lens package according to claim 12, wherein the polymeric lens body comprises a reaction product of a polymerizable composition comprising 25 wt% to 55 wt% of a siloxane monomer or a combination of siloxane monomers, 30 wt% to 55 wt% of a vinyl monomer selected from NVP, VMA, or a combination thereof; optionally 1 wt% to 20 wt% of a hydrophilic monomer selected from N,N-dimethylacrylamide (DMA), 2-hydroxyethyl methacrylate (HEMA), ethoxyethyl methacrylamide (EOEMA), or ethylene glycol methyl ether methacrylate (EGMA), or any combination thereof; and / or optionally 1 wt% to 20 wt% of a hydrophobic monomer selected from methyl methacrylate (MMA), isobornyl methacrylate (IBM), or 2-hydroxybutyl methacrylate (HOB) or any combination thereof. Claim 14 A sealed contact lens package according to any one of claims 1 to 3, wherein the contact lens comprises fanfilcon A, comfilcon A, somofilcon A, riofilcon A, or stenfilcon A. Claim 15 A sealed contact lens package according to any one of claims 1 to 3, comprising a base member having a well for holding a packaging solution and a contact lens, and a cover forming a liquid-tight seal with the base member. Claim 16 A method for manufacturing a sealed contact lens package according to any one of claims 1 to 3, comprising the following steps: (a) polymerizing a polymerizable composition in a contact lens mold to obtain a polymeric lens body; (b) extracting the polymeric lens body in an organic solvent containing a TRPM8 agonist in one or more steps; (c) hydrating the polymeric lens body in a hydration solution to obtain a silicone hydrogel contact lens; (d) placing a packaging solution containing the silicone hydrogel contact lens and a TRPM8 antagonist into a well of a contact lens packaging base member; (e) sealing the packaging base member to form a sealed contact lens package; and (f) autoclaving the package. Claim 17 A method according to claim 16, wherein at least a portion of the TRPM8 antagonist is distributed into a silicone hydrogel contact lens during the autoclaving step and is releasedly attached to a polymeric lens body.
Citation Information
Patent Citations
Pharmaceutical composition for the treatment of dry eye
US20170071875A1
WS12-releasing contact lens
US20220350163A1
